Ethyl-EPA in Huntington disease

2005141 citationsJournal Article

Authors

Basant K. Puri · Hammersmith Hospital

Blair R. Leavitt · University of British Columbia

Michael R. Hayden · University of British Columbia

Christopher A. Ross

Adam Rosenblatt · Johns Hopkins University

J. Timothy Greenamyre · Emory University

Steven J. Hersch · Harvard University Press

Abstract

Ethyl-eicosapentaenoate (ethyl-EPA) (purity > 95%) had no benefit in the intent-to-treat cohort of patients with Huntington disease, but exploratory analysis revealed that a significantly higher number of patients in the per protocol cohort, treated with ethyl-EPA, showed stable or improved motor function. Further studies of the potential efficacy of ethyl-EPA are warranted.

Topics & Keywords

Genetic Neurodegenerative Diseases Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 65, Issue 2, pp. 286-292

DOI: 10.1212/01.wnl.0000169025.09670.6d

Field-Weighted Citation Impact: 4.22